patients patient resources clinical trials drug approval process learn more about ionis clinical trials pipeline r & d antisense technology discovery platform basic science antisense drugs medicinal chemistry antisense approaches intellectual property strategic alliances pharmaceutical partners satellite companies investors & media news & events press releases archived webcasts event calendar corporate governance board of directors board criteria director compensation and board meeting attendance committee composition certificates of incorporation bylaws code of ethics clawback policy rsu holding guidelines annual meeting stock information stock quote stock chart analyst coverage ownership profile financials annual reports sec filings shareholder services investor faq information request press kit careers available positions search open jobs browse open jobs edit your profile view submitted applications culture & values benefits equal opportunity intern program post doctoral program news october 8 2016new data presented at world muscle society congress support potential benefit of investigational treatment nusinersen in spinal muscular atrophymore september 28 2016ionis pharmaceuticals ceo dr. stanley crooke receives lifetime achievement award from the oligonucleotide therapeutics societymore september 26 2016biogen completes rolling submission of new drug application to fda for nusinersen as a treatment for spinal muscular atrophymore september 22 2016akcea announces publication in the lancet of clinical results with lp a lowering drugs designed to treat cardiovascular diseasemore spotlight chmp of the ema has granted nusinersen accelerated assessmentmore ionis receives drug discovery award to support cystic fibrosis researchmore newly published data demonstrate a novel pro inflammatory mechanism for lp a in humansmore newly published nusinersen clinical data highlight positive data in children with spinal muscular atrophymore clinical trials we have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions . more events no upcoming events at this time ... 1999 2016 ionis pharmaceuticals is a trademark of ionis pharmaceuticals inc. akcea therapeutics is a trademark of ionis pharmaceuticals inc. home contact terms of use and forward looking statements privacy policy about mission & values in the community management board of directors contact patients patient resources clinical trials drug approval process learn more about ionis clinical trials pipeline r & d antisense technology discovery platform basic science antisense drugs medicinal chemistry antisense approaches intellectual property strategic alliances pharmaceutical partners satellite companies investors & media news & events press releases archived webcasts event calendar corporate governance board of directors board criteria director compensation and board meeting attendance committee composition certificates of incorporation bylaws code of ethics clawback policy rsu holding guidelines annual meeting stock information stock quote stock chart analyst coverage ownership profile financials annual reports sec filings shareholder services investor faq information request press kit careers available positions search open jobs browse open jobs edit your profile view submitted applications culture & values benefits equal opportunity intern program post doctoral program